Latest news about Brawn Biotech
Brawn Biotech
21.05
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M+1.20%
6M+5.25%
1Y+27.96%
5Y-36.21%
More news about Brawn Biotech
14Feb 26
Brawn Biotech Limited Announces Q3 FY26 Financial Results for Quarter Ended December 31, 2025
Brawn Biotech Limited released its Q3 FY26 financial results for the quarter ended December 31, 2025, showing revenue from operations of ₹5.10 lakhs and a net loss of ₹0.78 lakhs. The results were approved by the Board of Directors and reviewed by statutory auditors in compliance with SEBI regulations.
30Jan 26
Brawn Biotech Limited Appoints Ms. Rati Garg as Chief Financial Officer
Brawn Biotech Limited appointed Ms. Rati Garg as Chief Financial Officer and Key Managerial Personnel effective February 1, 2026. The decision was approved during the board meeting held on January 30, 2026, based on the Nomination and Remuneration Committee's recommendation. Ms. Garg, a qualified Cost Accountant, brings over 15 years of experience in financial management, cost control, budgeting, regulatory compliance, and corporate finance to strengthen the company's financial leadership.
29Dec 25
Brawn Biotech Ltd Director Resignation - Mrs. Brij Bala Gupta Steps Down
Brawn Biotech Limited has announced the resignation of Director Mrs. Brij Bala Gupta, effective November 25, 2025, due to pre-occupation and unavoidable circumstances. The company initially communicated this to BSE on December 22, 2025, but provided additional documentation on December 29, 2025, after acknowledging it had inadvertently omitted the resignation letter copy in its earlier communication.
14Nov 25
Brawn Biotech Reports Net Loss of Rs. 7.44 Lacs in Q2 FY2026
Brawn Biotech Limited announced its Q2 FY2026 results, reporting a net loss of Rs. 7.44 lacs despite revenue from operations increasing to Rs. 797.00 lacs. Total revenue rose to Rs. 806.12 lacs, up from Rs. 588.86 lacs in Q1 FY2026 and Rs. 355.73 lacs in Q2 FY2025. Total expenses increased to Rs. 798.98 lacs. The company's balance sheet shows total assets of Rs. 2,215.67 lacs and total equity of Rs. 370.52 lacs as of September 30, 2025. Auditors Rajiv Udai & Associates conducted a limited review, finding no issues with the financial results' presentation.
30Sept 25
Brawn Biotech Shareholders Approve Key Resolutions at 40th AGM
Brawn Biotech Limited held its 40th Annual General Meeting on September 30, 2025, via video conferencing. Shareholders approved several important resolutions including the re-appointment of Mr. Amit Kumar as Manager for a five-year term, adoption of a new Memorandum of Association, approval of financial statements, and re-appointment of Mrs. Brij Bala Gupta as director. All resolutions received overwhelming support with 99.99% votes in favor. The meeting, chaired by Mr. Brij Raj Gupta, lasted from 11:00 AM to 11:13 AM, with e-voting open for an additional 30 minutes.
13Aug 25
Brawn Biotech Reports Turnaround with Rs 23.60 Lacs Profit in Q1
Brawn Biotech Limited, a pharmaceutical company, has reported a significant turnaround in its Q1 financial performance. The company posted a profit of Rs 23.60 lacs, compared to losses in previous quarters. Revenue increased substantially to Rs 579.77 lacs, more than doubling from the previous quarter. The company's Earnings Per Share (EPS) improved to Rs 0.89. The statutory auditor conducted a limited review and found no issues with the financial results.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,782.20
(+0.12%)
6,623.00
(+0.40%)
4,420.90
(+1.87%)
1,401.30
(+0.19%)
1,089.00
(+0.41%)
1,278.20
(+0.84%)
2,267.70
(+0.80%)
2,336.10
(-0.72%)
1,462.30
(-0.09%)
1,446.80
(+1.37%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
